Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare CVE:AEX NASDAQ:PHAR On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAEXAEX GoldC$0.62-1.6%C$0.62C$0.44▼C$0.82C$109.80MN/A28,496 shs8,500 shsPHARPharming Group$12.92-0.4%$16.01$8.69▼$21.34$912.55M0.0423,900 shs8,789 shsBeginner's Guide To Retirement StocksClick the link to see MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAEXAEX Gold0.00%0.00%0.00%0.00%0.00%PHARPharming Group-0.92%-19.79%-23.53%-15.23%+29.70%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAEXAEX GoldC$0.62-1.6%C$0.62C$0.44▼C$0.82C$109.80MN/A28,496 shs8,500 shsPHARPharming Group$12.92-0.4%$16.01$8.69▼$21.34$912.55M0.0423,900 shs8,789 shsBeginner's Guide To Retirement StocksClick the link to see MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAEXAEX Gold0.00%0.00%0.00%0.00%0.00%PHARPharming Group-0.92%-19.79%-23.53%-15.23%+29.70%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAEXAEX Gold 0.00N/AN/AN/APHARPharming Group 2.40Hold$38.33196.65% UpsideCurrent Analyst Ratings BreakdownLatest JOG, GENL, PHAR, and AEX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/11/2026PHARPharming Group Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeHold (C-) ➝ Sell (D)4/27/2026PHARPharming Group Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (D+) ➝ Hold (C-)4/13/2026PHARPharming Group Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeHold (C-) ➝ Sell (D+)4/10/2026PHARPharming Group Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong Sell ➝ Hold4/10/2026PHARPharming Group Canaccord Genuity GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$37.003/30/2026PHARPharming Group Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (D+) ➝ Hold (C-)3/24/2026PHARPharming Group HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$37.003/13/2026PHARPharming Group Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeHold (C-) ➝ Sell (D+)3/13/2026PHARPharming Group OppenheimerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform$42.00 ➝ $41.003/12/2026PHARPharming Group HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price TargetBuy$37.00(Data available from 5/14/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAEXAEX GoldN/AN/AC$0.13 per share4.59C$0.21 per shareN/APHARPharming Group$376.13M2.43$0.20 per share65.27$3.81 per share3.39Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAEXAEX GoldN/A-C$0.14N/AN/AN/AN/AN/AN/AN/APHARPharming Group$2.85M$0.1680.7719.88N/A3.30%4.64%2.55%7/30/2026 (Estimated)Latest JOG, GENL, PHAR, and AEX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/7/2026Q1 2026PHARPharming Group$0.05-$0.07-$0.12-$0.07$92.06 million$72.45 million3/12/2026Q4 2025PHARPharming Group$0.15$0.07-$0.08$0.07$111.76 million$106.50 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthAEXAEX GoldN/AN/AN/AN/AN/APHARPharming GroupN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAEXAEX Gold2.0919.9019.77PHARPharming Group0.352.632.06Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAEXAEX GoldN/APHARPharming Group0.03%Insider OwnershipCompanyInsider OwnershipAEXAEX GoldN/APHARPharming Group2.07%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAEXAEX GoldN/A177.10 millionN/ANot OptionablePHARPharming Group28070.62 million69.16 millionNot OptionableJOG, GENL, PHAR, and AEX HeadlinesRecent News About These CompaniesPharming Group N.V. Recorded A 21% Miss On Revenue: Analysts Are Revisiting Their ModelsMay 10, 2026 | finance.yahoo.comPharming Group (PHAR) Gets a Buy from Canaccord GenuityMay 9, 2026 | theglobeandmail.comPharming Group (NASDAQ:PHAR) Lowered to Hold Rating by Wall Street ZenMay 9, 2026 | marketbeat.comPharming Group Q1 Earnings Call HighlightsMay 8, 2026 | marketbeat.comPharming Group (NASDAQ:PHAR) Issues Quarterly Earnings ResultsMay 7, 2026 | marketbeat.comPharming Group reports first quarter 2026 financial results; on track for Joenja® U.S. pediatric label expansion and launches in Japan and Europe in 2026May 7, 2026 | markets.businessinsider.comPharming Group announces presentations at CIS 2026 Annual Meeting, including leniolisib pediatric data in APDS and clinical experience in CVID and related disordersMay 7, 2026 | markets.businessinsider.comPharming Group N.V. (PHAR) Q1 2026 Earnings Call TranscriptMay 7, 2026 | seekingalpha.comPharming Group (NASDAQ:PHAR) Shares Gap Down After Earnings MissMay 7, 2026 | marketbeat.comPharming Group N.V. 2026 Q1 - Results - Earnings Call PresentationMay 7, 2026 | seekingalpha.comPharming earnings in focus: Can rare disease growth offset Q1 dip?May 6, 2026 | investing.comPharming Group (XAMS:PHARM) Q1 2026: Everything You Need To Know Ahead Of EarningsMay 6, 2026 | finance.yahoo.comPharming Group (PHAR) to Release Earnings on ThursdayMay 6, 2026 | americanbankingnews.comPharming Group ADR PHGMay 5, 2026 | morningstar.comMHigh Growth Tech Stocks To Watch In May 2026May 5, 2026 | finance.yahoo.comPharming Group N.V. Sponsored ADR (NASDAQ:PHAR) Given Average Rating of "Moderate Buy" by BrokeragesMay 5, 2026 | marketbeat.comPharming Group (PHAR) Expected to Announce Quarterly Earnings on ThursdayApril 30, 2026 | marketbeat.comPharming Group N.V. Sponsored ADR (NASDAQ:PHAR) Sees Significant Decline in Short InterestApril 28, 2026 | marketbeat.comAnalysts Offer Insights on Healthcare Companies: Pharming Group (PHAR) and Kura Oncology (KURA)April 24, 2026 | theglobeandmail.comPharming Group N.V. Sponsored ADR (NASDAQ:PHAR) Sees Large Decline in Short InterestApril 17, 2026 | marketbeat.comPharming Group NV - Depositary receipt (PHAR) price target increased by 43.79% to 25.84April 16, 2026 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesThe Real SpaceX Play: 5 Chip Stocks Powering the IPO Before It LaunchesBy Bridget Bennett | May 4, 20265 Stocks Positioned to Win the AI Data Center BuildoutBy Bridget Bennett | April 20, 20263 Healthcare Stocks Set to Benefit From the One Big Beautiful BillBy Chris Markoch | May 10, 2026The Most Important Part of These 3 Big Pharma Earnings Reports Wasn’t the BeatBy Jessica Mitacek | May 2, 2026Hims & Hers Stock Plunges After Q1 Miss: Is the GLP-1 Pivot Enough to Fuel a Recovery?By Jessica Mitacek | May 12, 2026JOG, GENL, PHAR, and AEX Company DescriptionsAEX Gold CVE:AEXC$0.62 -0.01 (-1.59%) As of 07/11/2022AEX Gold Inc. engages in the acquisition, exploration, and development of mineral properties in Greenland. It holds interests in licenses covering an area of 7,615.85 square kilometers located in South Greenland. The company was formerly known as Alopex Gold Inc. and changed its name to AEX Gold Inc. in June 2018. AEX Gold Inc. was incorporated in 2017 and is headquartered in Toronto, Canada.Pharming Group NASDAQ:PHAR$12.92 -0.05 (-0.37%) As of 12:53 PM Eastern This is a fair market value price provided by Massive. Learn more.Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company offers RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome. It also develops OTL-105, an investigational ex-vivo autologous hematopoietic stem cell gene therapy for the treatment of HAE. The company has a development collaboration and license agreement with Novartis; and a strategic collaboration agreement with Orchard Therapeutics plc for research, development, manufacturing, and commercialization of OTL-105. Pharming Group N.V. was incorporated in 1988 and is headquartered in Leiden, the Netherlands. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Dividend Growth or High Yield: The Income Investor's Bet Nebius Upside Expands as AI Feedback Loop Intensifies Oklo Stock Could Be Ready for Another Massive Run Insider Trades: Okta and Abbott See Buys, Micron Insiders Sell Qualcomm Stock Doubles: New Era? Or Another False Start? D-Wave Earnings Looked Weak, But Investors May Be Missing This A Quantum Shift: Why Speculative Money Is Ditching AI A New Focus for GoPro: Is a Takeover in the Frame? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
